Skip to main content

OCIAD1 Antibody [Janelia Fluor® 585]

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-97855JF585

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Immunohistochemistry-Paraffin

Label

Janelia Fluor 585

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Produced in rabbits immunized with E. coli-derived Human OCIAD1 fragment.

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for OCIAD1 Antibody [Janelia Fluor® 585]

Application
Recommended Usage

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen and protein A Affinity-purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: OCIAD1

Alternate Names

Asrij, MGC111072, OCIA domain containing 1, OCIA domain-containing protein 1, OCIAFLJ20455, Ovarian carcinoma immunoreactive antigen, TPA018

Gene Symbol

OCIAD1

Additional OCIAD1 Products

Product Documents for OCIAD1 Antibody [Janelia Fluor® 585]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for OCIAD1 Antibody [Janelia Fluor® 585]



Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...